Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Share-based Compensation (2016 - 2025)

Protalix BioTherapeutics has reported Share-based Compensation over the past 16 years, most recently at $732000.0 for Q4 2025.

  • Quarterly results put Share-based Compensation at $732000.0 for Q4 2025, up 11.93% from a year ago — trailing twelve months through Dec 2025 was $2.3 million (down 29.39% YoY), and the annual figure for FY2025 was $2.3 million, down 29.39%.
  • Share-based Compensation for Q4 2025 was $732000.0 at Protalix BioTherapeutics, up from $598000.0 in the prior quarter.
  • Over the last five years, Share-based Compensation for PLX hit a ceiling of $1.4 million in Q4 2023 and a floor of $36000.0 in Q3 2022.
  • Median Share-based Compensation over the past 5 years was $543000.0 (2023), compared with a mean of $558300.0.
  • Biggest five-year swings in Share-based Compensation: crashed 88.43% in 2021 and later soared 441.67% in 2023.
  • Protalix BioTherapeutics' Share-based Compensation stood at $418000.0 in 2021, then grew by 28.95% to $539000.0 in 2022, then skyrocketed by 153.62% to $1.4 million in 2023, then tumbled by 52.16% to $654000.0 in 2024, then grew by 11.93% to $732000.0 in 2025.
  • The last three reported values for Share-based Compensation were $732000.0 (Q4 2025), $598000.0 (Q3 2025), and $427000.0 (Q2 2025) per Business Quant data.